B Group, Inc. 13F holdings, Q4 2025
Holdings as of December 31, 2025 · filings on SEC EDGAR · latest filing →
B Group, Inc. disclosed 15 US equity positions worth $134.9m in its Q4 2025 13F filing. The largest position was ADMA at 33.2% of the reported book, followed by CLLS and PALI. Against the Q3 2025 filing, it opened 2 new positions, added to 2 and reduced 2 among the top 15 holdings.
What did B Group, Inc. own in Q4 2025? Top 15 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2025 |
|---|---|---|---|---|---|---|---|
| 1 | ADMA ADMA BIOLOGICS INC | Healthcare | 33.2% | $44.8m | 2,457,542 | 2% | added |
| 2 | CLLS CELLECTIS S A | 11.8% | $15.9m | 3,281,501 | 0% | held | |
| 3 | PALI PALISADE BIO INC | Healthcare | 7.8% | $10.6m | 4,500,000 | – | new |
| 4 | TSHA TAYSHA GENE THERAPIES INC | Healthcare | 7.3% | $9.9m | 1,800,556 | 0% | held |
| 5 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 7.3% | $9.8m | 33,237 | 6% | added |
| 6 | SGHT SIGHT SCIENCES INC | 5.4% | $7.3m | 920,000 | -1% | reduced | |
| 7 | ZLAB ZAI LAB LTD | Healthcare | 5.2% | $7.1m | 400,000 | 0% | held |
| 8 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 4.6% | $6.3m | 90,000 | – | new |
| 9 | ASMB ASSEMBLY BIOSCIENCES INC | Healthcare | 4.4% | $6.0m | 175,706 | 0% | held |
| 10 | IOVA IOVANCE BIOTHERAPEUTICS INC | Healthcare | 3.0% | $4.1m | 1,500,000 | 0% | held |
| 11 | SYRE SPYRE THERAPEUTICS INC | 2.4% | $3.3m | 100,000 | 0% | held | |
| 12 | AURA AURA BIOSCIENCES INC | 2.3% | $3.1m | 572,576 | 0% | held | |
| 13 | RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 2.3% | $3.1m | 135,000 | 0% | held |
| 14 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 1.7% | $2.3m | 75,000 | 0% | held |
| 15 | APGE APOGEE THERAPEUTICS INC | Healthcare | 1.1% | $1.5m | 20,000 | -43% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.